Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (697)	2/18/1998 4:54:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1826

David, <<It is also the level that will make Adam happy.>> Somehow I doubt it <g>. I think the following is much more likely: <<Let's shrink some tumors.>> Peter

To: David Cathcart who wrote (697)	2/18/1998 9:40:00 PM
From: the eagle	Read Replies (1) \| Respond to of 1826

david, i think that you posted some info attributable to blitzer regarding the outlook for a european partner for distribution. it sounded like info blitzer gave at an annual stockholders meeting. i wish you could give us the benefit of those comments again so we might read between the lines. it seems that mogn wants to keep the north american market all to mogn and let the other deals pay for the trials. again, mogn has great mgt, great balance sheet, on the road to profitabilty, a potential blockbuster drug, and the potential to have someone else to bear the cost of bringing the drug to market. seems to me mogn has very little downside risk and a tremendous upside for those that are patient.